Brands of olodaterol
This list is not intended to be exhaustive.
Inhaled: Striverdi®
Inhaled (combination products, with antimuscarinic): Spoilto®, Yanimo®
Issues for surgery
Increased risk of exacerbation of chronic obstructive pulmonary disease (COPD) if omitted.
Advice in the perioperative period
Elective and emergency surgery
Continue (including combination products).
There are number of inhaled preparations which contain olodaterol, either as a single agent or in combination products with antimuscarinics – all of these can be continued pre-operatively. Check active ingredients of currently available preparations in British National Formulary.
Advise patients who are prescribed regular olodaterol inhaled products but do not usually take them regularly to do so pre-operatively to optimise disease control prior to anaesthesia.
Confirm the inhaler brand, strength and device with the patient.
Post-operative advice
Restart post-operatively as soon as next dose is due.
Interactions with common anaesthetic agents
Halogenated anaesthetics
Olodaterol may cause hypokalaemia. Concomitant use with medications that prolong the QT-interval (e.g. desflurane, isoflurane, sevoflurane and possibly thiopental) increases the risk of torsades de pointes. Monitor serum potassium and QT-interval with concomitant treatment.
Interactions with other common medicines used in the perioperative period
Corticosteroids
Dexamethasone and hydrocortisone may cause hypokalaemia which would potentiate any olodaterol-mediated hypokalaemia. Hypokalaemia increases the risk of torsades de pointes with medications which prolong the QT-interval e.g. antiemetics (domperidone, droperidol, granisetron, haloperidol, ondansetron and possibly prochlorperazine), antimicrobials (ciprofloxacin, clarithromycin, erythromycin) and loperamide.
Further information
None relevant.
References
Baxter K, Preston CL (eds), Stockley’s Drug Interactions (online) London: Pharmaceutical Press. http://about.medicinescomplete.com [Accessed on 27th June 2021]
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http://about.medicinescomplete.com [Accessed on 27th June 2021]
Summary of Product Characteristics – Striverdi® (olodaterol) Respimat 2.5 microgram, solution for inhalation. Boehringer Ingelheim Limited. Accessed via www.medicines.org.uk 27/06/2021 [date of revision of the text January 2021]